

Institute Name	JAWAHARLAL NEHRU MEDICAL COLLEGE, BELAGAVI
-----------------------	--------------------------------------------------

India Ranking 2017 ID	IR17-MEDI-2-1-N002
------------------------------	--------------------

Discipline	MEDICAL
-------------------	---------

Parameter	Consultancy Projects						
2D.FPPP	S.No.	Financial Year	Name of faculty (Chief Consultant)	Client Organization	Title of Consultancy of project	Amount received (in Rupees)	Amount received (in words)
	1	2015-16	Dr. Rajesh Powar, Dr. K.M. Keluskar, Dr. Kotrashetti Department of Plastic Surgery, Pediatric Surgery, Oral and Maxillofacial Surgery, Orthodontics and DentofacialOrthopae dics	Smile Train, USA	1. KLE'S Smile Train project	69,00,000/-	Sixty Nine Lakh only

		<p>Dr. B.S. Kodkany Dr. S.S. Goudar, Dr. N.S. Mahantshetti Dr. M.B. Bellad Dr. R.M. Bellad Dr. S.M. Dhaded Dr. YeshitaPujar Dr. HemaDhumale Dr. M.c. Metgud</p> <p>Dept. of Paediatrics, ObG, Physiology, Community Medicine of J.N. Medical College, Belagavi</p>	<ul style="list-style-type: none"> • NIH, USA • NICHD, USA • Global Implementation Task Force of American Academy of Pediatrics, USA • Bill and Melinda Gate's Foundation, USA • WHO, Thrasher Research Fund, USA • International Atomic Energy Agency, Vienna • RHR Division of World Health Organization, Geneva, Switzerland • University of Colorado Health Sciences Center 	<ul style="list-style-type: none"> • Research on Women and child Health • Maternal and Newborn Health Registry (MNH Registry)Dept. of OBG & Paediatrics • Helping babies breathe initiative Dept. of Paediatrics • The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial • Dept. of OBG • Does Implementation of Helping Babies Breathe (HBB) save lives? • Dept. of Paediatrics • Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, India 	21,88,000/-	Twenty one lakhs eighty eight thousand
		<p>Dr. M.V. Jali Dr. R.S. Mudhol</p> <p>KLE Dr. Prabhakar Kore Hospital & MRC, Belagavi</p>	Govt. of Karnataka Insurance companies	<ol style="list-style-type: none"> 2. Yashaswini, 3. Balasanjivini, 4. Arogya Bhagya, 5. Vajapayee Arogyashree Scheme, 6. Ex-servicemen Contributory Health Scheme (ECHS), 7. Employee's State Insurance (ESI), DBCS 	6,18,91,767/-	Six crore eighteen lakh ninety one thousand seven hundred and sixty seven

			Dr .V. A. Kothiwale - PI Dr.Aditya.Kulkarni-S ub-I Dr. M S Ganachari- CRC Bhupendra Parihar- CRC Disha Khoda- CRC	Norwich	8. Protocol title: "A proof of concept, parallel design, single treatment, double arm trial of 50 mg quick dissolve tablets containing freeze dried Lactobacillus delbrueckii subsp. bulgaricus lysate (GenCix™) from FraXon technologies Inc., USA, conducted on treatment naïve chronic hepatitis C positive patients in one arm and treatment naïve chronic hepatitis C positive patients on dialysis in the other"	40,000/-	Forty thousand
--	--	--	-------------------------------------------------------------------------------------------------------------------------------------------	---------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------

			Dr. Gajanan.S.Gaude – PI Dr.V.A.Kothiwale –Sub-I	Glenmark	9.Protocol Number: GPL-CT/20111011/III“A Phase III, randomized, open label, Non- inferiority, active-controlled comparative, parallel group, multicentric study of fixed dose combination of formoterol 12 µg plus fluticasone 250 µg as DPI (Test Drug) with the commercially available fixed dose combination of Salmeterol 50µg and Fluticasone250 µg (Seretide™ Accuhaler™ 50/250 µg) as DPI in a 12-week Treatment period of adolescent and adult subjects with moderate-severe stable persistent asthma”	40,000/-	Forty thousand
--	--	--	--------------------------------------------------------	----------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------

			Glenmark	10.Protocol title - C003 – “A double blind, randomized, placebo controlled, parallel group, three arm, multicenter and multinational pivotal study to assess the efficacy and safety of two dosage regimens of Crofelemer tablets in the treatment of moderate to severe acute watery diarrhea in adult patients.”	40,000/-	Forty thousand	
			Dr.N.S.Mahantshetti- PI Dr. Joshi- Sub-I	Bharat Biotech	11.Protocol title -“A phase II/III randomized, single blinded, active controlled study to evaluate the immunogenicity and safety of inactivated Japanese encephalitis vaccine in healthy volunteers”.	50,000/-	Fifty thousand

			Dr. V.D.Patil - PI Dr. Preeti Amarkhed-Sub I Dr.M S Ganachari - CRC	Biological E. Limited	12. Trial no: BECT/JEV-PII-III/018, Protocol no: bect018/jev-pii-iii/ctp-02 "A multicentric, open label randomized controlled phase ii/iii study to evaluate the safety and immunogenicity of be's inactivated je vaccine in healthy ≥ 1 to <3 year old Indian children"	45,000/-	Forty five thousand
				Panacea	13. Protocol number: PBL/CR/0032008/CT "A randomized, multicenter, open label, comparative study to evaluate the Immunogenicity and reactogenicity of a new fully liquidpentavalentDTw P-Hib-IPV vaccine <i>EasyfourPol™</i> , Panacea Biotec Ltd) with tetravalent DTwP/Hib vaccine (<i>TetrAct-Hib™</i>), co-administered with <i>Imovax Polio®</i> (Salk Based Inactivated Polio Vaccine) of Sanofi Pasteur India Pvt. Ltd. In healthy infants.	40,000/-	Forty thousand

				Reliance	14. Protocol number :RLS/TP/2010/03:“Prospective, multicentric, open label, clinical study to evaluate efficacy and safety of R-TPR-004 in patients undergoing treatment for acute ischemic stroke”	25,000/-	Twenty five thousand
				Quintile	15. Protocol number: DU176b-C-U305: “A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (lmw) heparin/edoxaban versus (LMW) Heparin/Warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism”	30,000/-	Thirty thousand

				George Institute	16. Protocol number BC22140 ALEGLITAZAR (R00728804): "Phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled study cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ASC) event and type 2 diabetes mellitus (T2D)"	20,000/-	Twenty thousand
			Dr. M. Khanpet - PIDr. Vinayak Ekbot - Sub IDr. M S	Clinigene, International Ltd	17. Protocol title: "A phase II, randomized, open label, single	30,000/-	Thirty thousand
				Quintile	18. Protocol number: DU176b-C-U301: "A Phase 3, randomised, double-blind, double dummy,	35,000/-	Thirty five thousand
				GlaxoSmithKline	19. Protocol title: "A phase III, open-label, randomized, multicenter study to evaluate the	30,000/-	Thirty thousand

			Dr .V. A. Kothiwale – PI Dr. M. S. Ganachari -CRC Khoremand Bhathena-CRC Atul.Aggrawal-CRC	Thrombosis Research Institute	20Protocol number TRI08888 GARFIELD:“Prospective, multicentre, international registry of male and female patients newly diagnosed with atrial fibrillation”.	50,000/-	Fifty thousand
				SHAN Pharmaceuticals	21Protocol Study Number: SH501:“Safety, immune lot-to-lot consistency and non- inferiority of Shan 5 (DTwP-HepB-Hib) vaccine in comparison to pentavac SD when administered as a single booster dose at 15-18 months and three dose at 6-8,10-12 and 14-16 weeks of age in healthy indian children and infants”	30,000/-	Thirty thousand
				Glenmark	22.Protocol number: GPL/CT/2012/III: “A randomised, double-blind, comparative, prospective, multicentre, parallel study to assess efficacy, safety and tolerability of Repaglidine/Metformin IR tablet monotherapy or repaglidine tablet monotherapy in adult	35,000/-	Thirty five thousand

			Dr. M.V. Jali -PI	ICON Clinical Research-Company	23.Protocol number: CV181169 :A multicentre, randomised, double-blind, active-controlled, parallel group, phase 3 trial to evaluate the safety of add-on therapy with Saxagliptin and Dapagliflozin added to Metformin compared to add-on therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects with type 2 Diabetes who have inadequate glycemic control on Metformin alone.”	45,000/-	Forty five thousand
				Glenmark	24. Protocol number: GRC17536-203: “A Phase 2, 4-week randomized, double-blind, parallel group, placebo controlled proof of concept study to evaluate efficacy, safety and tolerability of grc 17536 in patients with painful diabetic peripheral neuropathy.”	30,000/-	Thirty thousand

			Dr. M.V. Jali -PI	Piramal Healthcare	25.Protocol number: P2202/47/10: "A Phase II, randomized, double-blind, placebo-controlled, dose-ranging, two-staged, fixed design study to evaluate the efficacy, safety, tolerability and pharmacokinetics of p2202 in overweight/obese patients of type 2 diabetes mellitus inadequately controlled on metformin, sulphonyl urea, or both."	50,000/-	Fifty thousand
			Dr .V. A. Kothiwale - PI S Ganachari- CRC Tarang Shah - CRC	Amgen Technology Pvt.ltd	26.Protocol no: 20110118:"A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease".	30,000/-	Thirty thousand

				Glenmark	27.Study title: "A Phase III prospective, randomized, open labelled, multicentric, parallel group, three arms clinical study to evaluate the efficacy and safety between monotherapy of Glenmark'sRoflumilast 500 Mcg Tablet and Combination Therapy of Roflumilast 500 Mcg Tablet Plus Tiotropium 9 mcg inhalation and combination therapy of roflumilast 500 mcg tablet plus salmeterol 25mcg inhalation in adult patients with chronic obstructive pulmonary disease (COPD)."	25,000/-	Twenty five thousand
--	--	--	--	----------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------------

				Serum Institute	28.Protocol title: "A multicentric randomized , comparative clinical trial to assess the immunogenicity and reactogenicity of DPTw [meat free] vaccine with standard commercially available DPTw [routine] vaccine in Indian children aged 6 -14 weeks".	40,000/-	Forty thousand
				Reliance	29.Protocol title: To study the safety and efficacy of R-TPR -001 (Reteplase-Recombinant plasminogen activator) in patients with acute myocardial infarction and ST segment elevation".	20,000/-	Twenty thousand

				Novonordisk	30.Protocol title: EX 1000-1919: A multicentre, multinational, randomized, open labeled, two armed, parallel group trial with a 24 week treatment period comparing the efficacy and safety of two concentrations of Mixtard 30 (333IU/mL) or Mixtard 30 (1000IU/mL)".	20,000/-	Twenty thousand
				SMO India.	31.Protocol title: A Phase III , multicenter, randomized , double – blind study to evaluate the efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes mellitus and chronic renal insufficiency who have inadequate glycemic control"	30,000/-	Thirty thousand
			Medical director Medical Superintendent	Govt. of Karnataka	Balasanjeevini Vajapayee Arogya Scheme	2,00,25,342	Two crore twenty five thousand three hundred forty two
	2	2014-15					

			13 Dr.Rajesh Powar	· Smile Train,USA	1. KLE,S Smile Train project	71,59,000/-	Seventy One Lakh Fifty Nine Thousand only/-
--	--	--	--------------------	-------------------	------------------------------	-------------	---------------------------------------------

			14	<ul style="list-style-type: none"> • NIH, USA • NICHD, USA Global Implementation Task Force of American Academy of Pediatrics, USA Bill and Melinda Gate's Foundation, USA WHO, Thrasher Research Fund, USA International Atomic Energy Agency, Vienna • RHR Division of 	<p>2. Research on Women and child Health</p> <p>3. Maternal and Newborn Health Registry (MNH Registry) Dept. of OBG & Paediatrics</p> <p>4. Helping babies breathe initiative Dept. of Paediatrics</p> <p>5. The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial Dept. of OBG</p> <p>6. Does Implementation of Helping Babies Breathe (HBB) save lives? Dept. of Paediatrics</p> <p>7. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, India Dept. of OBG & Paediatrics</p>	20,82,000/-	Twenty lakhs eighty two thousand
			15	<p>15. Govt. of Karnataka Insurance companies</p>	<ul style="list-style-type: none"> • Yashaswini, • Balasanjivini, • Arogya Bhagya, • Vajapayee Arogyashree Scheme, • Ex-servicemen Contributory Health Scheme (ECHS), • Employe's State Insurance (ESI), DBCS 	5,09,72,744/-	Five crore nine lakh seventy two thousand seven hundred and forty four

			Dr.(Mrs)N.S.Mahants hetti -PI	18.Biological E. Limited – Company	18. Protocol title: A Multicentric double blind single arm randomized phase IV study to evaluate the safety, reactogenicity and lot consistency of three production lots of BE's combined liquid Pentavalent DTwP-rHepB- HIB vaccine administered at 6-10-14 weeks schedule to 6-8 week old healthy Indian infants.	75,000/-	Seventy thousand
				19.SMO India – CRO	19. Protocol no: GLP114130: “A randomized, double-blind, active-controlled, parallel group, multicenter study to determine the efficacy and safety of Albiglutide as compared with Sitagliptin in subjects with type 2 Diabetes mellitus with renal impairment”	80,000/-	Eighty thousand

				20.Abbott	20 Protocol title: A prospective multicenter observational study to characterize the patient population with cholestasis in chronic liver disease due to non-alcoholic liver disease receiving heptral in India[P13-163]	70,000/-	Seventy thousand
				21. Panacea Biotec Ltd	21.Protocol number: PBL/CR/0032008/CT “A randomized, multicenter, open label, comparative study to evaluate the immunogenicity and reactogenicity of a new fully liquid Pentavalent DTwP-Hib-IPV vaccine (easyfourPol™,) with tetravalent DTwP/Hib vaccine (TetrAct-Hib™), co-administered with Imovax Polio® (Salk Based Inactivated Polio Vaccine) of Sanofi Pasteur India Pvt. Ltd. In Healthy Infants.	1,00,000/-	One lakh

				22.ICON	22. Protocol no: MB102073: "A multicenter, randomized, double-blind, placebo- controlled, parallel group, phase iii trial to evaluate the safety and efficacy of dapagliflozin in subjects with type 2 Diabetes with inadequately controlled Hypertension on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker".	50,000/-	Fifty thousand
--	--	--	--	---------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------

				23	23. Protocol no: MB102077: "A multicentre, randomized, double-blind, placebo-controlled, parallel group, phase III trial to evaluate the safety and efficacy of Dapagliflozin in subjects with type @ Diabetes with inadequately controlled hypertension treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and an additional antihypertensive medication".	40,000/-	Forty thousand
--	--	--	--	----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------

				24.Clinigene International Ltd	24. Protocol number: MK-0822: “Phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of Odanacatib (mk-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium”.	50,000/-	Fifty thousand
--	--	--	--	--------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------	----------------

			Dr. V.D.Patil - PI Dr. Preeti Amarkhed- Sub I Dr.M S Ganachari - CRC	25. Biological E. Limited - Company	25. Trial no: BECT/JEV-PII- III/018, Protocol no: bect018/jev-pii-iii/ctp-02 "A multicentric, open label randomized controlled phase II/III study to evaluate the safety and immunogenicity of be's inactivated JE vaccine in healthy ≥ 1 to <3 year old Indian children"	70,000/-	Seventy thousand
			Medical director Medical Superintendent	Govt. of Karnataka	Balasanjeevini Vajapayee Arogya Scheme	1,61,61,443	One crore Sixty one lakhs sixty one thousand four hundred forty three
	3	2013-14					
			Dr.Rajesh. Power	· Smile train USA	1. KLE'S Smile Train project	69,12,000/-	Sixty Nine Lakh Twelve thousand Only

				<p>PHD, USA</p> <ul style="list-style-type: none"> • NICHD, USA • Global Implementation Task Force of American Academy of Pediatrics, USA • Bill and Melinda Gate's Foundation, USA • WHO, Thrasher Research Fund, USA • International Atomic Energy Agency, Vienna • RHR Division of World Health Organization, Geneva, Switzerland • University of Colorado Health Sciences Center • The Children 	<p>Research on Women and Child Health</p> <ul style="list-style-type: none"> • Maternal and Newborn Health Registry (MNH Registry) Dept. of OBG & Paediatrics • Helping babies breathe initiative Dept. of Paediatrics • The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial Dept. of OBG • Does Implementation of Helping Babies Breathe (HBB) save lives? Dept. of Paediatrics • Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, India Dept. of OBG & Paediatrics • Emergency obstetrics 	20,58,000/-	Twenty lakhs fifty eight thousand
--	--	--	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------	-----------------------------------

				Govt. of Karnataka Insurance companies	<ul style="list-style-type: none"> • Yashaswini, • Balasanjivini, • Arogya Bhagya, • Vajapayee Arogyashree Scheme, • Ex-servicemen Contributory Health Scheme (ECHS), • Employee's State Insurance (ESI), DBCS • Psychiatry Day Care Center <p>KLE Dr. Prabhakar Kore Hospital & MRC Belagavi</p>	3,55,71,688/-	Three crore fifty five lakh seventy one thousand six hundred and eighty eight
			Dr. M.V. Jali -PI	ICON Clinical Research-Company	2. Protocol no: CV181169 : "A multicentre, randomised, double-blind, active-controlled, parallel group, phase 3 trial to evaluate the safety of add-on therapy with saxagliptin and dapagliflozin added to metformin compared to add-on therapy with saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in subjects with Type 2 Diabetes who have inadequate glyceemic control on metformin alone".	29,97,000/-	Twenty nine lakhs ninety thousand

				Glenmark - Company	3. Protocol title - C003 - a double blind, randomized, placebo controlled, parallel group, three arm, multicenter and multinational pivotal study to assess the efficacy and safety of two dosage regimens of crofelemer tablets in the treatment of moderate to severe acute watery diarrhea in adult patients.	70,000	Seventy thousand
				ZYDUS	4. Protocol no:CLR_10_22 :“Efficacy and safety of SPIL’s Lubriprostone capsule, 24 mcg Lubriprostone in subjects with chronic idiopathic constipation : randomized, double blind, parallel group, active and placebo controlled, clinical endpoint bioequivalence study”.	30000/-	Thirty thousand

			Dr. Jayaprakash Appajigol-PI	SUN PHARMA	5. Protocol no: ZYH 1.12.001.01 PROT: "A multicenter, prospective, randomized, open label phase IV clinical study to evaluate the safety and efficacy of saroglitazar (ZYH1) as compared to fenofibrate in patients with dyslipidemia".	50,000/-	Fiftythousand
			Dr. M.V. Jali -PI	ELI LILLY	6. Protocol title: "A demonstration project to evaluate the effectiveness and acceptability of the joint diabetes evaluation (JADE) & diabetes monitoring database(Diamond) programs in Type 2 Diabetes patients in India".	50,000/-	Fiftythousand

				ELI LILLY	7.Protocol title: Protocol I4V-MC-JADX: A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with inadequate response to conventional disease-modifying antirheumatic drugs with moderately to severely active rheumatoid arthritis.	60,000/-	Sixty thousand
			Dr. Udapudi-PI	ELI LILLY	8.Protocol title: Protocol I4V-MC-JADZ- “A randomized, double-blind, active-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderately to severely active rheumatoid arthritis who have had limited or no treatment with disease modifying antirheumatic drugs”.	45,000/-	Forty five thousand

			Dr.S.Udapudi-PI	ELI LILLY	9.Protocol title: I4V-MC-JADY(C): "A Phase 3, multicenter study to evaluate the long-term safety and efficacy of baricitinib in patients with rheumatoid arthritis".	40,000/-	FortyThousand
			Dr.Rajendra.Bhandan kar- PIDr. Sudheer Yadwad- Sub I	ELI LILLY	10.Protocol SB2-G31-RA: "A randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to remicade® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy".	60,000/-	Sixty thousand

				ELI LILLY	11.Protocol I4L-MC-ABEL: “A prospective, randomized, open-label comparison of a long acting basal insulin analog, LY2963016, to lantus® in combination with mealtime insulin lispro in adult patients with type 1 diabetes mellitus: the element 3 study”.	50,000/-	Fifty thousand
				BBIL	12. Protocol title: “Addendum to typhoid Vi polysaccharidetetanus toxoid protein conjugate phase III clinical trial protocol entitled:A phase III, Randomized,multicentre ,controlled study to evaluate the immunogenicity and safety of BBIL’s typhoid Vi capsular polysaccharide –tetanus toxoid protein conjugate vaccine (Typbar TCV) Vs. Referencevaccine (typbar) in healthy subjects.”.	40,000/-	Forty thousand

				ZYDUS	13.Reference protocol no: CLR_13_14:Study Title: “Pharmacodynamic efficacy and safety of Leuprolide depot 7.5 mg (SPIL) in subjects with Prostatic Adenocarcinoma”.	50,000/-	Fifty thousand
				BBIL	14. Protocol No: BBIL/JEV/IV/2012A: “A Phase IV Single dose, Open labeled, Comparative, Randomized Controlled study to evaluate the Immunogenicity and Safety of BBIL’s JENVAC(Inactivated JE vaccine)Vs. Chinese SA-14-14-2(Live JE vaccine)vaccine in healthy volunteers”.	40,000/-	Forty thousand

				Ranbaxy	15. Ref: Protocol : "Comparative efficacy, safety and tolerability of FDC of cephalexin extended release (375mg) and Clavulanate Potassium (125 mg) tablets with Cephalexin extended release (375 mg) tablets in the treatment of uncomplicated skin and soft tissue infection - a randomized, double-blind study(study number: r2013006)".	60,000/-	Sixty thousand
				Ranbaxy	16. Ref: Protocol : "Comparative efficacy, safety and tolerability of FDC of Cephalexin extended release (375mg) and Clavulanate Potassium (125 mg) tablets with cephalexin extended release (375 mg) tablets in the treatment of upper respiratory tract infections - a randomized, double-blind study (study number: r2013006)".	30,000/-	Thirty thousand

			Dr.Jayprakash Appajigol – PI	Asahi Kasei Pharma America Company	17.Ref:3-001 A randomized double-blind, placebo-controlled, Phase-3 study to assess the safety and efficacy of ART-123 in subject with severe sepsis and coagulopathy.	30,000/-	Thirty thousand
			Dr.Rajendra.Bhandan kar-PI	Sristek Company	18. Protocol title: “A multicenter, double-blind, vehicle controlled, parallel-group study comparing a generic Diclofenac Sodium topical gel, 1% in the treatment of subjects with osteoarthritis of the knee”.	30,000/-	Thirty thousand

				BBIL	19. Protocol no.: BBIL/ROTA/IV/2013: "Phase IV, multicenter, randomized, single-blind, study to evaluate the immunogenicity, reactogenicity& safety of the live attenuated rotavirus vaccine ROTAVAC® as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants".	45,000/-	Forty five thousand
				Merc Company	20. Protocol title: MK-0822-083-00: "An observational follow-up study for: a phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of Odanacatib (MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium (protocol 018)".	60,000/-	Sixty thousand

				Himalaya Drug Company, Bengaluru	21. "A comparative clinical study to evaluate the efficacy and safety of two cystone formulations in patients suffering from urolithiasis".	30,000/-	Thirty thousand
				Progene Research Laboratories, Belagavi	22. "A Randomized, controlled, double blind study to evaluate the efficacy and safety of capsule progen in improving parameters of semen analysis in cases of male infertility due to defect in seminal parameters'.	30,000/-	Thirty thousand
			Medical director Medical Superintendent	Govt. of Karnataka	Balasanjeevini Vajapayee Arogya Scheme	1,29,23,090	One crore twenty nine lakhs twenty three thousand ninety